Mi
MiNT Therapeutics
Stockholm SEFounded 201915 employees
Private CapbiotechPrivateHematology
Platform: Gene Reg Hem
Market Cap
N/A
All Drugs
3
Clinical Trials
5
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Adagrafotisoran | MIN-6673 | Phase 2/3 | 2 | IL-17A | Hemophilia AMM | ||
| Fixaratamab | MIN-6740 | Phase 1/2 | 2 | PD-L1 | Urothelial CaADPKD | ||
| MIN-7010 | MIN-7010 | Phase 1 | 1 | WEE1 | Pancreatic Ca |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)